Evidence map›Paper›PMID 26052916›Full record

ArticleBone marrow transplantation2015

High-resolution HLA matching in unrelated donor transplantation in Switzerland: differential impact of class I and class II mismatches may reflect selection of nonimmunogenic or weakly immunogenic DRB1/DQB1 disparities.

J R Passweg, U Schanz, Y Chalandon, T Güngör, H Baldomero, D Heim, G Nair, M Medinger, S Masouridi-Levrat, G N de Faveri and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. HLA Matching in Unrelated Stem Cell Transplantation up to Date.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

J R PasswegDivision of Hematology, University Hospital Basel, Basel, Switzerland.
U SchanzDivision of Hematology, University Hospital, Zürich, Switzerland.
Y ChalandonService d'Hématologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
T GüngörDivision of Immunology, University Children's Hospital, Zürich, Switzerland.
H BaldomeroSBST Data Office, University Hospital Basel, Basel, Switzerland.
D HeimDivision of Hematology, University Hospital Basel, Basel, Switzerland.
G NairDivision of Hematology, University Hospital, Zürich, Switzerland.
M MedingerDivision of Hematology, University Hospital Basel, Basel, Switzerland.
S Masouridi-LevratService d'Hématologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
G N de FaveriDonor Registry, Swiss Transfusion SRC, Bern, Switzerland.
J-M TiercyNational Reference Laboratory for Histocompatibility (LNRH), Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Swiss Blood Stem Cell Transplantation Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unrelated donor searches in Switzerland require high-resolution HLA typing for HLA-A/B/C/DRB1/DRB3,4/DQB1 loci. We evaluated this strategy accepting donors with ⩾9/10 match. Of 802 unrelated donor transplants in 2000-2013, 570 were 10/10 matched, 31 were DRB3/4 mismatched, 261 were single-allele mismatched and 13 had 2 allele mismatches. Of the 261 single-allele disparities, 60 concerned HLA-A/-B, 55 HLA-C and 73 HLA-DRB1/-DQB1 loci. Transplants were reduced intensity conditioning (289, 36%), marrow (187, 23%), EBMT risk score was low in 39, intermediate I in 331, intermediate II in 333 and high in 99 patients. Five-year survival was 48±4%. HLA affected survival in the multivariate model adjusted for risk score. HLA-A/-B and HLA-C mismatches had twice the mortality risks, whereas HLA-DRB1/-DQB1 mismatches were similar to matched transplants. HLA-DRB3/4 mismatches were associated with a nonsignificant increased mortality risk. HLA-DRB3/4 mismatches had higher graft-versus-host disease and transplant-related mortality risks and lower relapse rates compared with matched transplants. We show significant effects of HLA class I, but not HLA class II, mismatches. The lack of impact of DRB1 disparities may be related to the lower immunogenicity of the DRB1*11:01/11:04 and DRB1*14:01/14:54 mismatches, representing 46% of DRB1 incompatibilities. These results support a matching algorithm that prioritizes mismatches considered as more permissive.

Indexed as

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationHistocompatibility TestingUnrelated DonorsAdolescentAdultAgedAllograftsChildChild, PreschoolDisease-Free SurvivalDonor SelectionFemaleHistocompatibility Antigens Class IHLA-DQ beta-ChainsHLA-DRB1 ChainsHistocompatibility Antigens Class IHLA-DQB1 antigenHLA-DQ beta-ChainsHLA-DRB1 Chains

Identifiers

PMID26052916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.